|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0014582,
umls-concept:C0035696,
umls-concept:C0205251,
umls-concept:C0246415,
umls-concept:C0441889,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1334331,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-6-19
|
|
pubmed:abstractText |
Putative tumor suppressor genes LATS1 and LATS2 are implicated in the regulation of the cell cycle at the G2/M and G1/S phase, respectively. This study investigated possible correlations of intra-tumoral LATS1 and LATS2 mRNA levels with response to epirubicin plus cyclophosphamide (EC) or docetaxel (DOC) treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/GMNN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/LATS1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/LATS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/MIB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ubiquitin-Protein Ligases,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0171-5216
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
501-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17297610-Adult,
pubmed-meshheading:17297610-Aged,
pubmed-meshheading:17297610-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17297610-Breast Neoplasms,
pubmed-meshheading:17297610-Cell Cycle Proteins,
pubmed-meshheading:17297610-Cyclophosphamide,
pubmed-meshheading:17297610-Epirubicin,
pubmed-meshheading:17297610-Female,
pubmed-meshheading:17297610-Humans,
pubmed-meshheading:17297610-Immunohistochemistry,
pubmed-meshheading:17297610-Middle Aged,
pubmed-meshheading:17297610-Neoplasm Staging,
pubmed-meshheading:17297610-Polymerase Chain Reaction,
pubmed-meshheading:17297610-Predictive Value of Tests,
pubmed-meshheading:17297610-Prognosis,
pubmed-meshheading:17297610-Protein-Serine-Threonine Kinases,
pubmed-meshheading:17297610-RNA, Messenger,
pubmed-meshheading:17297610-Taxoids,
pubmed-meshheading:17297610-Treatment Outcome,
pubmed-meshheading:17297610-Tumor Markers, Biological,
pubmed-meshheading:17297610-Tumor Suppressor Proteins,
pubmed-meshheading:17297610-Ubiquitin-Protein Ligases
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
|
|
pubmed:affiliation |
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka 565-0871, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
